Taltz
Prescription
Biologic (IL-17A Inhibitor)
Ixekizumab Injection
Manufacturer: Eli Lilly
Description
Taltz is Eli Lilly's ixekizumab — a humanised monoclonal antibody targeting IL-17A with among the highest PASI 90/100 response rates in psoriasis trials. Provides rapid onset of clearance. Used for moderate-to-severe plaque psoriasis and psoriatic arthritis.
Active Compounds
No tracked compounds
Indications
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
Dosage
160mg subcutaneous injection at week 0, then 80mg at weeks 2, 4, 6, 8, 10, 12, then 80mg every 4 weeks.
Formulations
Full Ingredient List
- Ixekizumab
- Sodium Citrate Dihydrate
- Citric Acid Anhydrous
- Sodium Chloride
- Polysorbate 80
- Water for Injection
Side Effects
- Injection site reactions
- Upper respiratory infections
- Oral candidiasis
- Nausea
- Tinea infections
Warnings
- Screen for tuberculosis before starting
- Increased mucocutaneous candidiasis risk
- May worsen inflammatory bowel disease
- Avoid live vaccines
- Neutropenia monitoring recommended initially